Keely Hooks
Nurse Practitioner · Birmingham, ALNPI 1912305269
Payments from drug & device makers
Across 274 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$578
- Bayer$574
- Novo Nordisk$518
- Lilly USA, LLC$513
- Amgen$504
- AstraZeneca$289
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,958100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $578 |
| Bayer | 28 | $574 |
| Novo Nordisk | 31 | $518 |
| Lilly USA, LLC | 31 | $513 |
| Amgen | 34 | $504 |
| AstraZeneca | 14 | $289 |
| Exact Sciences | 19 | $283 |
| Pfizer | 16 | $283 |
| Shield Therapeutics Inc | 13 | $246 |
| AbbVie | 12 | $234 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $151 |
| Abbott | 5 | $117 |
| Dexcom, Inc. | 5 | $109 |
| Tris Pharma Inc | 4 | $74 |
| Supernus Pharmaceuticals, Inc. | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Noven Therapeutics, LLC | 2 | $41 |
| Merck | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Almatica Pharma LLC | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $17 |
| Pulmonx Corporation | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$4,958 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $62,605 |
| EliquisApixaban | 44 | $39,998 |
| JardianceEmpagliflozin | 36 | $38,614 |
| MounjaroTirzepatide | 30 | $31,128 |
| JanuviaSitagliptin Phosphate | 22 | $27,804 |
| QuliptaAtogepant | 11 | $11,248 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,242 |
| LinzessLinaclotide | 13 | $11,057 |
| Atorvastatin Calcium | 268 | $4,489 |
| Rosuvastatin Calcium | 100 | $2,256 |
| Losartan Potassium | 126 | $1,847 |
| Levothyroxine Sodium | 143 | $1,690 |
| Famotidine | 115 | $1,681 |
| Trazodone Hcl | 79 | $1,633 |
| Duloxetine Hcl | 52 | $1,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $518 | $62,60548 claims |
| PfizerEliquis | $283 | $39,99844 claims |
| Boehringer IngelheimJardiance | $33 | $38,61436 claims |
| Lilly USA, LLCMounjaro | $513 | $31,12830 claims |
| MerckJanuvia | $38 | $27,80422 claims |
| AbbVieQulipta, Linzess | $234 | $22,30524 claims |
| GSKTrelegy Ellipta | $578 | $11,24216 claims |
| Almatica Pharma LLCSertraline Hcl | $21 | $53760 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Birmingham
- Ginger McDanielBirmingham$27K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
- Lisa PeoplesBirmingham$17K
- Samantha WeaverBirmingham$17K
- Logan GilmoreBirmingham$13K
- Jennifer CothronBirmingham$13K
- Chelsea KelleyBirmingham$13K
- Vanessa HillBirmingham$11K
- Heather BuffingtonBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.